Results 61 to 70 of about 10,843,846 (251)

Extrapulmonary Small Cell Carcinoma of the Stomach: A Lethal Entity

open access: yesCase Reports in Gastroenterology, 2010
Extrapulmonary small cell carcinoma of the stomach is a rare and aggressive malignancy with a poor prognosis that was first described in 1976 by Matsusaka et al.
Duane Moise   +8 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

open access: yesFEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang   +2 more
wiley   +1 more source

Cetuximab and biomarkers in non-small-cell lung carcinoma

open access: yesBiologics: Targets & Therapy, 2012
Nitin Patil, Mohammed Abba, Heike AllgayerDepartment of Experimental Surgery, Medical Faculty Mannheim, University of Heidelberg and Molecular Oncology of Solid Tumors Unit, German Cancer Research Center (DKFZ), Heidelberg, GermanyAbstract: Cancer ...
Patil N, Abba M, Allgayer H
doaj  

Liver organoids: modelling complexity in homeostasis and disease

open access: yesFEBS Letters, EarlyView.
Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley   +1 more source

Solid ovarian teratoma with carcinoid tumor and small cell neuroendocrine carcinoma in a 68-year-old patient: A case report

open access: yesHuman Pathology Reports, 2022
We present the first reported case of a 68-year-old woman with an adrenal metastasis from a small cell carcinoma arising in an ovarian teratoma. The patient initially presented with an adrenal small cell carcinoma that was postulated to be a metastasis ...
Dallas Hampton   +2 more
doaj   +1 more source

Epigenetic reprogramming of lineage switching in cancer

open access: yesFEBS Letters, EarlyView.
Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı   +4 more
wiley   +1 more source

Ligand‐dependent transcriptional heterogeneity in cell cycle gene expression delays G1/S entry

open access: yesFEBS Letters, EarlyView.
EGF and HRG induce distinct G1/S progression programs in ErbB2‐amplified BT474 breast cancer cells. Despite activating the potent ErbB2–ErbB3 heterodimer, HRG does not accelerate cell‐cycle entry. Instead, EGF promotes earlier restriction‐point passage via ERK–FOS signaling, whereas HRG activates the AKT–MYC axis, driving transcriptional heterogeneity ...
Ririn Rahmala Febri   +5 more
wiley   +1 more source

Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways [PDF]

open access: yes, 2013
The DNA-damaging agent camptothecin (CPT) and its analogs demonstrate clinical utility for the treatment of advanced solid tumors, and CPT-based nanopharmaceuticals are currently in clinical trials for advanced kidney cancer; however, little is known ...
Ashcroft, M   +4 more
core   +2 more sources

Clinical outcome of incidentally discovered small renal cell carcinoma after delayed surgery

open access: yesCancer Management and Research, 2013
Koichi Sugimoto,1,2 Nobutaka Shimizu,1 Takashi Oki,2 Kazuhiro Nose,2 Tsukasa Nishioka,2 Shogo Adomi,3 Takayuki Ohzeki,3 Atsunobu Esa,3 Hirotsugu Uemura11Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Osaka, Japan; 2Department ...
Sugimoto K   +8 more
doaj  

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

open access: yesMolecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy